Aytu biopharma announces strategic shift to focus on commercial operations and indefinite suspension of clinical development programs

Following a corporate review, aytu biopharma is indefinitely suspending clinical development and removing expenses related to ar101/enzastaurin, healight, and nt0502, and focusing on revenue growth and near-term cash flow generation aytu is expecting to generate positive quarterly adjusted ebitda in the first half of calendar 2023 expected future clinical development savings of more than $20m englewood, co / accesswire / october 13, 2022 / aytu biopharma, inc. (the company or "aytu") (nasdaq:aytu), a pharmaceutical company focused on commercializing novel therapeutics, today announced a shift of the company's strategy aimed at accelerating the growth of its commercial business and achieving profitability. as a result, the company is announcing the indefinite suspension of its clinical development programs, including ar101/enzastaurin for the treatment of vascular ehlers-danlos syndrome (veds).
AYTU Ratings Summary
AYTU Quant Ranking